CRISPR/Cas9 delivery by NIR-responsive biomimetic nanoparticles for targeted HBV therapy.

Dan WangLing ChenChengbi LiQuanxin LongQing YangAilong HuangHua Tang

Published in: Journal of nanobiotechnology (2022)

The UCNPs-based biomimetic nanoplatforms achieved the inhibition of HBV replication via CRISPR therapy and it is a potential system for efficient treatment of human HBV diseases.

Keyphrases

fluorescence imaging
hepatitis b virus
crispr cas
photodynamic therapy
genome editing
liver failure
endothelial cells
cancer therapy
genome wide
drug delivery
mesenchymal stem cells
climate change
tissue engineering
human health
combination therapy
drug release